Ambryon Biosciences

AAV8 Serotype

Highly efficient liver-tropic serotype widely used in clinical hepatic gene therapy. Discovered from rhesus macaque tissue. Superior liver transduction versus AAV2.

TropismLiver (primary), muscle, CNS (moderate), pancreas

Characteristics

10-100 fold higher liver transduction than AAV2. Fast onset of transgene expression (1-2 weeks). Moderate pre-existing immunity (~40% seropositive). Uses laminin receptor (LamR) for hepatocyte binding. Efficient hepatocyte transduction at low doses. Good safety profile in clinical trials.

Applications

Hemophilia A and B gene therapy (multiple clinical trials). Liver-directed metabolic disorders. Ornithine transcarbamylase deficiency. Glycogen storage diseases. Acute intermittent porphyria. Most common serotype for liver gene therapy trials.

Sequence1 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Nathwani et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med — Nathwani 2011 Hemophilia B

Identifiers & revision